Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9479
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKawaguchiya, Mitsuyo-
dc.contributor.authorUrushibara, Noriko-
dc.contributor.authorUrushibara, Noriko-
dc.contributor.authorOhashi, Nobuhide-
dc.contributor.authorTakamatsu, Rika-
dc.contributor.authorTsutida, Sho-
dc.date.accessioned2024-12-20T07:42:00Z-
dc.date.available2024-12-20T07:42:00Z-
dc.date.issued2023-12-
dc.identifier.citationShort Communicationen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9479-
dc.description.abstractAbstract Ten years after the introduction of the pneumococcal conjugate vaccine (PCV) in Japan, the prevalence rates of non-PCV13 and non-PCV20 serotypes among pediatric pneumococcal isolates were 94.0% and 73.7%, respectively. The predominant non-PCV13/PCV20 serotypes (15A, 35B, and 23A) were mostly multidrug-resistant ( 80.5%), exhibiting nonsusceptibility to penicillin. Copyright ª 2023, Taiwan Socien_US
dc.language.isoen_USen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectStreptococcus pneumoniaeen_US
dc.subjectSerotypeen_US
dc.subjectAntimicrobial susceptibilityen_US
dc.subjectPneumococcal conjugate vaccines (PCVs)en_US
dc.subjectJapanen_US
dc.titleSpread of multidrug resistance in nonPCV13/PCV20 serotypes of Streptococcus pneumoniae: A cross-sectional study ten years after the introduction of pneumococcal conjugate vaccine in Japanen_US
dc.typeArticleen_US
Appears in Collections:VOL 56 NO 6 2023

Files in This Item:
File Description SizeFormat 
1288-1292.pdf502.24 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.